Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$107M in Q4 2023 → $229M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | 92.9% | Unchanged | 7,903,838 | $213M |
| Phathom Pharmaceuticals, Inc. | 7.1% | Unchanged | 1,493,854 | $16.2M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 05, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Added | +64,840 | +$720K | 7.2% |
quarter ended December 31, 2025 · filed February 10, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | Trimmed | −1,000,000 | −$36.3M | 92.4% |
| Phathom Pharmaceuticals, Inc. | Added | +261,900 | +$4.34M | 7.6% |
quarter ended September 30, 2025 · filed November 14, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 13, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed August 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | Added | +259,259 | +$4.12M | 95.1% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Hillevax, Inc. | Exited | −236,379 | −$416K | — |
| Phathom Pharmaceuticals, Inc. | Added | +44,542 | +$362K | 8.2% |
quarter ended September 30, 2024 · filed November 12, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Added | +400,610 | +$7.24M | 16.2% |
| Mineralys Therapeutics, Inc. | Trimmed | −550,000 | −$6.66M | 83.5% |
| Hillevax, Inc. | Trimmed | −972,595 | −$1.71M | 0.3% |
Loading...
